Timeliness of the Oncology Drug Review Process for Public Funding in Canada
1
QEII Health Sciences Centre, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada
2
Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK
3
School of Pharmacy, Dalhousie University, Halifax, NS B3H 2Y9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(5), 279-281; https://0-doi-org.brum.beds.ac.uk/10.3747/co.24.3825
Submission received: 6 July 2017
/
Revised: 4 August 2017
/
Accepted: 2 September 2017
/
Published: 1 October 2017
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The oncology drug review process for public funding in Canada (Figure 1) encompasses both. [...]
Share and Cite
MDPI and ACS Style
Younis, T.; Skedgel, C. Timeliness of the Oncology Drug Review Process for Public Funding in Canada. Curr. Oncol. 2017, 24, 279-281. https://0-doi-org.brum.beds.ac.uk/10.3747/co.24.3825
AMA Style
Younis T, Skedgel C. Timeliness of the Oncology Drug Review Process for Public Funding in Canada. Current Oncology. 2017; 24(5):279-281. https://0-doi-org.brum.beds.ac.uk/10.3747/co.24.3825
Chicago/Turabian StyleYounis, T., and C. Skedgel. 2017. "Timeliness of the Oncology Drug Review Process for Public Funding in Canada" Current Oncology 24, no. 5: 279-281. https://0-doi-org.brum.beds.ac.uk/10.3747/co.24.3825
